ANAVEX LIFE SCIENCES CORP. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 11.54 million shares for the 12-month period ending 2021-09-30, per its 10-K filed 2021-11-24.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2021-11-24
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2019-12-31 was 9.23M shares, a 17.13% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-12-31 was 7.88M shares, a 8.71% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-12-31 was 7.25M shares, a 17.57% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-12-31 was 6.16M shares, a 30.26% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 11.54M shares, a 9.12% increase from fiscal 2020.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 10.58M shares, a 20.01% increase from fiscal 2019.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2019 was 8.81M shares, a 22.65% increase from fiscal 2018.
- ANAVEX LIFE SCIENCES CORP. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 7.19M shares, a 7.06% increase from fiscal 2017.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2021-09-30 | 11.54M shares 10-K · filed 2021-11-24 | |||
| 2020-09-30 | 10.58M shares 10-K · filed 2021-11-24 | |||
| 2020-06-30 | 10.58M shares 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 10.49M shares 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | 9.23M shares 10-Q · filed 2020-02-06 | |||
| 2019-09-30 | 8.81M shares 10-K · filed 2020-12-28 | |||
| 2019-06-30 | 8.82M shares 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | 7.66M shares 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 7.88M shares 10-Q · filed 2019-02-07 | |||
| 2018-09-30 | 7.19M shares 10-K · filed 2019-12-16 | |||
| 2018-06-30 | 8.45M shares 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 7.48M shares 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | 7.25M shares 10-Q · filed 2018-02-07 | |||
| 2017-09-30 | 6.71M shares 10-K · filed 2019-01-25 | |||
| 2017-06-30 | 6.75M shares 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | 6.05M shares 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | 6.16M shares 10-Q · filed 2017-02-07 | |||
| 2016-09-30 | 6.01M shares 10-K · filed 2017-12-11 | |||
| 2016-06-30 | 3.73M shares 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | 3.69M shares 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | 4.73M shares 10-Q · filed 2016-02-08 | |||
| 2015-09-30 | 6.10M shares 10-K · filed 2016-12-14 | |||
| 2014-09-30 | 26.97M shares 10-K · filed 2015-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |